The effect of hydroxyurea in spinal muscular atrophy cells and patients

BACKGROUND Spinal muscular atrophy (SMA) is a degenerative motor neuron disease caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene. Effective treatment for SMA is unavailable at present. The aim of this study was to investigate the effect of hydroxyurea (HU) in SMA cells and patients. MATERIALS AND METHODS Fifteen SMA lymphoid and three fibroblast cell lines, 2 from SMA patients and 1 control, were treated with HU at different concentrations, and 33 patients (types II, III) randomized into three groups on different HU dosage, 20, 30, 40 mg/kg/day, were treated for 8 weeks and followed up for another drug-free 8 weeks. The effect of HU on SMN2 gene expression and clinical manifestations was evaluated. RESULTS After treatment, in vitro, full-length mRNA level and gems number increased significantly, and hnRNP A1 protein decreased. In vivo, there were slight increases in muscle strength scores at 4 weeks and full-length SMN mRNA at 8 weeks in 30 mg/kg/day subgroup. CONCLUSIONS Treating with HU enhanced SMN2 gene expression in SMA cells and showed slight trend towards improvement in some clinical outcome measures in SMA patients which suggests HU may be safe to use in SMA patients but larger randomized, placebo-controlled, double-blind trials are needed to further investigate its efficacy.

[1]  J. Mendell,et al.  Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. , 1997, American journal of human genetics.

[2]  J. Manley,et al.  SR proteins and splicing control. , 1996, Genes & development.

[3]  A. Krainer,et al.  Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1 , 2002, Nature Genetics.

[4]  Y. Hofmann,et al.  Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. , 2003, Human molecular genetics.

[5]  C. Lorson,et al.  SRp30c-dependent stimulation of survival motor neuron (SMN) exon 7 inclusion is facilitated by a direct interaction with hTra2 beta 1. , 2002, Human molecular genetics.

[6]  A. Ross,et al.  Neuronal differentiation triggered by blocking cell proliferation. , 1992, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[7]  Susanna M. Grzeschik,et al.  Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells , 2005, Annals of neurology.

[8]  S. Iannaccone,et al.  A phase 1 trial of riluzole in spinal muscular atrophy. , 2003, Archives of neurology.

[9]  J. Melki,et al.  The molecular bases of spinal muscular atrophy. , 2002, Current opinion in genetics & development.

[10]  K. Talbot.  Spinal muscular atrophy , 1999, Journal of Inherited Metabolic Disease.

[11]  Xiang-Dong Fu,et al.  The superfamily of arginine/serine-rich splicing factors. , 1995, RNA.

[12]  R. Abresch,et al.  Spinal muscular atrophy , 2010, Journal of the Neurological Sciences.

[13]  J. Pearn,et al.  Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. , 1978, Journal of medical genetics.

[14]  A. Schechter,et al.  Hydroxyurea therapy in β‐thalassaemia intermedia: improvement in haematological parameters due to enhanced β‐globin synthesis , 1995 .

[15]  E. Bertini,et al.  Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients , 2005, European Journal of Human Genetics.

[16]  B. Wirth,et al.  In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate , 2006, Annals of neurology.

[17]  R. Abresch,et al.  Serial manual muscle testing in Duchenne muscular dystrophy. , 1993, Archives of physical medicine and rehabilitation.

[18]  Arnold Munnich,et al.  Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.

[19]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Buyse,et al.  Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. , 1996, Blood.

[21]  A. D'Amico,et al.  Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy , 2007, Neurology.

[22]  J. Yong,et al.  Essential Role for the SMN Complex in the Specificity of snRNP Assembly , 2002, Science.

[23]  K. Fischbeck,et al.  Valproic acid increases SMN levels in spinal muscular atrophy patient cells , 2003, Annals of neurology.

[24]  P. Reichard,et al.  Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. , 1968, Cancer research.

[25]  M. Main,et al.  Pilot trial of albuterol in spinal muscular atrophy. , 2002, Neurology.

[26]  Hung Li,et al.  A mouse model for spinal muscular atrophy , 2000, Nature Genetics.

[27]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[28]  S. Ogino,et al.  Spinal muscular atrophy: molecular genetics and diagnostics , 2004, Expert review of molecular diagnostics.

[29]  T. Crawford,et al.  The survival motor neuron protein in spinal muscular atrophy. , 1997, Human molecular genetics.

[30]  R. Ware,et al.  Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. , 2004, Blood.

[31]  Elisa de Stanchina,et al.  Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. , 2006, American journal of human genetics.

[32]  G. Dover,et al.  Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. , 1987, Blood.

[33]  G. Dreyfuss,et al.  The SMN complex. , 2004, Experimental cell research.

[34]  J. Scott,et al.  Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. , 2005, Blood.

[35]  J. Goldberg,et al.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[36]  A. Flahault,et al.  Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients , 1998 .

[37]  J. Rappsilber,et al.  Gemin8 Is a Novel Component of the Survival Motor Neuron Complex and Functions in Small Nuclear Ribonucleoprotein Assembly* , 2006, Journal of Biological Chemistry.

[38]  E. Androphy,et al.  Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. , 2001, Human molecular genetics.

[39]  J. Manley,et al.  A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy , 2003, Nature Genetics.

[40]  J. Mendell,et al.  A placebo-controlled trial of gabapentin in spinal muscular atrophy , 2001, Journal of the Neurological Sciences.

[41]  Y. Jong,et al.  Molecular analysis of SMN, NAIP and P44 genes of SMA patients and their families , 2001, Journal of the Neurological Sciences.

[42]  G. Koren,et al.  Hydroxyurea use during pregnancy: A case report in sickle cell disease and review of the literature , 1999, American journal of hematology.

[43]  J. Vonsattel,et al.  Heterogeneity of subcellular localization and electrophoretic mobility of survival motor neuron (SMN) protein in mammalian neural cells and tissues. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Y. Jong,et al.  Treatment of spinal muscular atrophy by sodium butyrate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  E. Bertini,et al.  Pilot trial of phenylbutyrate in spinal muscular atrophy , 2004, Neuromuscular Disorders.

[46]  G. Dreyfuss,et al.  The Spinal Muscular Atrophy Disease Gene Product, SMN, and Its Associated Protein SIP1 Are in a Complex with Spliceosomal snRNP Proteins , 1997, Cell.

[47]  S. Iannaccone.  Spinal Muscular Atrophy , 1998, Seminars in neurology.

[48]  E. Bertini,et al.  Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy , 2004, European Journal of Human Genetics.

[49]  H. Lerner,et al.  Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. , 1965, Cancer chemotherapy reports.

[50]  A. Schechter,et al.  Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. , 1990, The New England journal of medicine.